Source - LSE Regulatory
RNS Number : 0894B
Dechra Pharmaceuticals PLC
08 June 2021
 

 

Tuesday, 8 June 2021

 

 

Dechra® Pharmaceuticals PLC

(Dechra, Group, Company)

 

 

Trading Update

 

 

The Board of Dechra is pleased to announce an update on trading and outlook for the current financial year.

 

In our interim release on 22 February 2021, we reported on our strong performance for the first seven months of the current financial year. The Group has continued to benefit from strong market fundamentals as well as lower Underlying Selling, General and Administration (SG&A) costs as a result of COVID-19. This, coupled with the completion of the UK pre-Brexit inventory unwind and further easing of lockdown restrictions, means the Board is increasingly confident that this strong performance will continue for the rest of this financial year.

 

Consequently, the Group now expects full year revenue to be ahead of current consensus expectations, with trading likely to be distributed more evenly than previously guided between the first and second halves of the financial year.

 

The Group plans to provide further details on its financial results for the year ending 30 June 2021 in a pre-close trading statement, expected to be issued on 12 July 2021.

 

 

 

Enquiries:

Dechra Pharmaceuticals PLC

 

Ian Page, Chief Executive Officer

Office:  +44 (0) 1606 814 730

Paul Sandland, Chief Financial Officer

e-mail: corporate.enquiries@dechra.com

Office:  +44 (0) 1606 814 730

 

 

 

TooleyStreet Communications Ltd

 

Fiona Tooley, Director

e-mail: fiona@tooleystreet.com

 

Mobile: +44 (0) 7785 703 523

Office:  +44 (0) 121 309 0099

 

 

About Dechra

Dechra is  a global specialist veterinary pharmaceuticals and relates products business.  Our expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. 

 

For more information, please visit: www.dechra.com

 

Stock Code: Full Listing (Pharmaceuticals): DPH

 

LEI: 213800J4UVB5OWG8VX82

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

Forward Looking Statement

This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document.  By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

 

Market Abuse Regulation (MAR)

The information contained within this announcement may constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFRMRTMTJMBRB
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.